验证数据展示
经过测试的应用
| Positive IF/ICC detected in | HeLa cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
CL488-84882-5 targets BCL3 in IF/ICC applications and shows reactivity with human, mouse samples.
| 经测试应用 | IF/ICC Application Description |
| 经测试反应性 | human, mouse |
| 免疫原 | BCL3 fusion protein Ag13375 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | B-cell CLL/lymphoma 3 |
| 别名 | 242233B11, B-cell lymphoma 3 protein, BCL-3, BCL4, D19S37 |
| 计算分子量 | 446 aa, 47 kDa |
| 观测分子量 | 48-60 kDa |
| GenBank蛋白编号 | BC064993 |
| 基因名称 | BCL3 |
| Gene ID (NCBI) | 602 |
| 偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
| 最大激发/发射波长 | 493 nm / 522 nm |
| 形式 | Liquid |
| 纯化方式 | Protein A purification |
| UNIPROT ID | P20749 |
| 储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| 储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
BCL3 (B-cell lymphoma 3 protein) has seven ankyrin repeat domains, a proline-rich N terminal domain and a serine- and proline-rich C-terminal domain (PMID: 31930327). BCL3 is an important contributor to chronic inflammatory disease states, such as osteoarthritis and rheumatoid arthritis (PMID: 12483727). BCL3 is a predominantly nuclear protein containing a trans-activation domain, and it can be recruited to NF-κB-responsive promoters, resulting in transcriptional activation or repression depending on the subunit composition of NF-κB complexes (PMID: 25089799, PMID: 30135206). BCL3 is known to be overexpressed in human breast cancers and is associated with reduced metastasis-free survival (PMID: 38255248).
实验方案
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 488 BCL3 antibody CL488-84882-5 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |